SAB Biotherapeutics ( (SABS) ) has issued an update.
SAB Biotherapeutics announced at the EASD Annual Meeting that their Phase 1 clinical trial of SAB-142, a novel immunotherapy for Type 1 diabetes, has successfully completed enrollment with healthy volunteers and is moving on to include patients with Type 1 diabetes. The treatment has shown a promising safety profile without the occurrence of serum sickness—a critical advantage over existing therapies. SAB-142 aims to modify the disease by delaying its onset and progression, and topline Phase 1 data is expected by the end of the year.
For detailed information about SABS stock, go to TipRanks’ Stock Analysis page.
